The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Stefano Cascinu, Maristella Bianconi et al.|Oncotarget|2015Cited by 46
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trialStefano Cascinu, Francesco Perrone, Stefania Mosconi et al.|European Journal of Cancer|2021Cited by 17
Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trialStefano Cascinu, Maria Carmela Piccirillo, Rossana Berardi et al.|Annals of Oncology|2019Cited by 4